Presentation is loading. Please wait.

Presentation is loading. Please wait.

Efficacy and safety of gemcabene as add-on to stable statin therapy in hypercholesterolemic patients  Evan Stein, MD, Harold Bays, MD, Michael Koren,

Published byClarence Shepherd Modified over 6 years ago

Similar presentations

Presentation on theme: "Efficacy and safety of gemcabene as add-on to stable statin therapy in hypercholesterolemic patients  Evan Stein, MD, Harold Bays, MD, Michael Koren,"— Presentation transcript:

1 Efficacy and safety of gemcabene as add-on to stable statin therapy in hypercholesterolemic patients 
Evan Stein, MD, Harold Bays, MD, Michael Koren, MD, Rebecca Bakker-Arkema, RPh, MS, Charles Bisgaier, PhD  Journal of Clinical Lipidology  Volume 10, Issue 5, Pages (September 2016) DOI: /j.jacl Copyright © 2016 National Lipid Association Terms and Conditions

2 Figure 1 Study design. After patient consent, statin therapy was stabilized and all other lipid-modifying medications were discontinued during a run-in phase of up to 12 weeks. Patients were screened (over 6 weeks) and then randomized 1:1:1 to either gemcabene 300 mg QD, 900 mg QD, or matching placebo for 8 weeks. Low-density lipoprotein cholesterol (LDL-C); once daily (QD). Journal of Clinical Lipidology  , DOI: ( /j.jacl ) Copyright © 2016 National Lipid Association Terms and Conditions

3 Figure 2 Patient disposition. A total of 211 patients were screened, 66 patients were randomized, and 61 patients completed the study. Withdrew (W/D); adverse event (AE). Journal of Clinical Lipidology  , DOI: ( /j.jacl ) Copyright © 2016 National Lipid Association Terms and Conditions

4 Figure 3 Gemcabene effects on mean percent change in LDL-C, non-HDL-C, ApoB, and median percent change in CRP. LDL-C, low-density lipoprotein cholesterol; CRP, C-reactive protein; apoB, apolipoprotein B; non-HDL-C, non-high-density lipoprotein cholesterol. Journal of Clinical Lipidology  , DOI: ( /j.jacl ) Copyright © 2016 National Lipid Association Terms and Conditions

Download ppt "Efficacy and safety of gemcabene as add-on to stable statin therapy in hypercholesterolemic patients  Evan Stein, MD, Harold Bays, MD, Michael Koren,"

Similar presentations

Corn oil improves the plasma lipoprotein lipid profile compared with extra-virgin olive oil consumption in men and women with elevated cholesterol: Results.

Corn oil improves the plasma lipoprotein lipid profile compared with extra-virgin olive oil consumption in men and women with elevated cholesterol: Results.
A Multiregional, Randomized Evaluation of the Lipid-Modifying Efficacy and Tolerability of Anacetrapib Added to Ongoing Statin Therapy in Patients With.

A Multiregional, Randomized Evaluation of the Lipid-Modifying Efficacy and Tolerability of Anacetrapib Added to Ongoing Statin Therapy in Patients With.
Interrupting bile-acid handling and lipid and glucose control: Effects of colesevelam on glucose levels  Michael H. Davidson, MD  Journal of Clinical.

Interrupting bile-acid handling and lipid and glucose control: Effects of colesevelam on glucose levels  Michael H. Davidson, MD  Journal of Clinical.
Flushing Profile of Extended-Release Niacin/Laropiprant Versus Gradually Titrated Niacin Extended-Release in Patients With Dyslipidemia With and Without.

Flushing Profile of Extended-Release Niacin/Laropiprant Versus Gradually Titrated Niacin Extended-Release in Patients With Dyslipidemia With and Without.
Lipid abnormalities in foreign-born and US-born patients in a medical group  Jawali Jaranilla, MD, MPH, Terese DeFor, MS, Gabriela Vazquez Benitez, PhD,

Lipid abnormalities in foreign-born and US-born patients in a medical group  Jawali Jaranilla, MD, MPH, Terese DeFor, MS, Gabriela Vazquez Benitez, PhD,
Patient and Physician Perspectives on Administration of the PCSK9 Monoclonal Antibody Alirocumab, an Injectable Medication to Lower LDL-C Levels†  Eli.

Patient and Physician Perspectives on Administration of the PCSK9 Monoclonal Antibody Alirocumab, an Injectable Medication to Lower LDL-C Levels†  Eli.
A randomized trial evaluating the efficacy and safety of alirocumab in South Korea and Taiwan (ODYSSEY KT)  Kwang Kon Koh, MD, PhD, FACC, Chang Wook Nam,

A randomized trial evaluating the efficacy and safety of alirocumab in South Korea and Taiwan (ODYSSEY KT)  Kwang Kon Koh, MD, PhD, FACC, Chang Wook Nam,
Charles R. Harper, MD, Terry A. Jacobson, MD  Mayo Clinic Proceedings 

Charles R. Harper, MD, Terry A. Jacobson, MD  Mayo Clinic Proceedings 
Volume 93, Issue 6, Pages (June 2018)

Volume 93, Issue 6, Pages (June 2018)
Corn oil improves the plasma lipoprotein lipid profile compared with extra-virgin olive oil consumption in men and women with elevated cholesterol: Results.

Corn oil improves the plasma lipoprotein lipid profile compared with extra-virgin olive oil consumption in men and women with elevated cholesterol: Results.
Efficacy and safety of the proprotein convertase subtilisin/kexin type 9 monoclonal antibody alirocumab vs placebo in patients with heterozygous familial.

Efficacy and safety of the proprotein convertase subtilisin/kexin type 9 monoclonal antibody alirocumab vs placebo in patients with heterozygous familial.
An assessment by the Statin Muscle Safety Task Force: 2014 update

An assessment by the Statin Muscle Safety Task Force: 2014 update
An assessment by the Statin Liver Safety Task Force: 2014 update

An assessment by the Statin Liver Safety Task Force: 2014 update
Purified palmitoleic acid for the reduction of high-sensitivity C-reactive protein and serum lipids: A double-blinded, randomized, placebo controlled.

Purified palmitoleic acid for the reduction of high-sensitivity C-reactive protein and serum lipids: A double-blinded, randomized, placebo controlled.
Charles R. Harper, MD, Terry A. Jacobson, MD  Mayo Clinic Proceedings 

Charles R. Harper, MD, Terry A. Jacobson, MD  Mayo Clinic Proceedings 
Omega-3 free fatty acids for the treatment of severe hypertriglyceridemia: The EpanoVa fOr Lowering Very high triglyceridEs (EVOLVE) trial  John J.P.

Omega-3 free fatty acids for the treatment of severe hypertriglyceridemia: The EpanoVa fOr Lowering Very high triglyceridEs (EVOLVE) trial  John J.P.
KDOQI Clinical Practice Guideline for Diabetes and CKD: 2012 Update

KDOQI Clinical Practice Guideline for Diabetes and CKD: 2012 Update
Emerging LDL therapies: Mipomersen—antisense oligonucleotide therapy in the management of hypercholesterolemia  Peter P. Toth, MD, PhD, FAAFP, FICA, FNLA,

Emerging LDL therapies: Mipomersen—antisense oligonucleotide therapy in the management of hypercholesterolemia  Peter P. Toth, MD, PhD, FAAFP, FICA, FNLA,
Omega-3 carboxylic acids in patients with severe hypertriglyceridemia: EVOLVE II, a randomized, placebo-controlled trial  Erik S.G. Stroes, MD, PhD, Andrey.

Omega-3 carboxylic acids in patients with severe hypertriglyceridemia: EVOLVE II, a randomized, placebo-controlled trial  Erik S.G. Stroes, MD, PhD, Andrey.
Glucagon-like peptide-1 receptor agonists reduced the low-density lipoprotein cholesterol in Japanese patients with type 2 diabetes mellitus treated with.

Glucagon-like peptide-1 receptor agonists reduced the low-density lipoprotein cholesterol in Japanese patients with type 2 diabetes mellitus treated with.

Similar presentations

Ads by Google